Daily Respiratory Research Analysis
Analyzed 210 papers and selected 3 impactful papers.
Summary
Analyzed 210 papers and selected 3 impactful articles.
Selected Articles
1. A motor thalamic site in humans that suppresses involuntary breathing without awareness.
Electrical stimulation localized to the anterior motor thalamus (VLa/VA) consistently induced unperceived central apnea in epilepsy patients, without impairing volitional breathing or speech. Stimulation of other forebrain regions generally did not affect respiration, and machine learning localized the apneic focus within VLa/VA, revealing a forebrain node capable of overriding brainstem respiratory control.
Impact: This is the first systematic human mapping showing a focal thalamic site that can suppress breathing without awareness, redefining forebrain contributions to respiratory control and informing disorders like central sleep apnea, SUDEP, and SIDS.
Clinical Implications: Caution is warranted for neuromodulation involving the anterior motor thalamus as stimulation may trigger apnea without patient awareness. The VLa/VA region emerges as a potential target for mechanistic studies and future therapies for central apnea disorders.
Key Findings
- Thalamic stimulation induced central apnea in all 11 participants across 412 stimulation trials.
- Apnea occurred most consistently with stimulation of the ventral lateral anterior (VLa) and ventral anterior (VA) motor thalamic nuclei.
- Volitional breathing and speech were preserved, indicating intact respiratory motor pathways.
- Stimulation of other forebrain regions (excluding amygdala) did not affect breathing.
- A machine learning algorithm localized the focal apneic region within anterior motor thalamus (centered in VLa extending into VA).
Methodological Strengths
- Extensive within-subject stimulation mapping (412 trials across 108 thalamic sites) enabling robust regional inference.
- Objective respiratory monitoring with preserved volitional function and machine learning-based anatomical localization.
Limitations
- Study population limited to patients undergoing iEEG for epilepsy, which may affect generalizability.
- Acute stimulation paradigms without long-term clinical outcome assessment.
Future Directions: Evaluate network connectivity and causal pathways from VLa/VA to brainstem centers, assess effects during natural sleep, and explore targeted neuromodulation strategies for central apnea disorders while ensuring safety.
Breathing is generated by brainstem respiratory networks but can be controlled and modulated by forebrain activity. The recent clinical adoption of thalamic electrode implantation during intracranial electroencephalography (iEEG) provides a rare opportunity to examine the role of the human thalamus in respiratory control. Here, we tested whether thalamic stimulation alters breathing in 11 patients undergoing iEEG for epilepsy monitoring. Across 412 stimulation trials at 108 thalamic sites, thalamic st
2. Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
The study uncovers BMAL1-mediated repression of PFKFB3 as a metabolic brake in alveolar macrophages and engineers an inhalable, AM-targeted nanoplatform (RM@TNT) to activate this axis in SA-ARDS. Inhaled RM@TNT suppresses AM glycolysis, inflammatory polarization, and oxidative stress, reducing lung injury and edema and significantly improving survival in SA-ARDS mice.
Impact: This work integrates mechanistic insight (BMAL1/PFKFB3 axis in AMs) with a targeted, multimodal inhalable DNA-nanostructure therapy that improves survival in SA-ARDS models, suggesting a new class of precision anti-inflammatory and metabolic therapies for critical respiratory failure.
Clinical Implications: While preclinical, the inhalable, macrophage-targeted approach and clear survival benefit support translational development for SA-ARDS. It highlights metabolic reprogramming (BMAL1/PFKFB3) as a therapeutic avenue in hyperinflammatory lung injury.
Key Findings
- BMAL1 binds the Pfkfb3 promoter in alveolar macrophages to repress PFKFB3, reducing glycolysis, M1 polarization, and pro-inflammatory cytokines/ROS.
- A biomimetic, ROS-responsive, inhalable nanoplatform (RM@TNT) delivers tetrahedral DNA nanostructures loaded with nobiletin (BMAL1 agonist) and Tuftsin to AMs.
- Inhaled RM@TNT prolongs pulmonary retention, targets AMs, suppresses AM glycolysis and inflammation, attenuates lung injury and edema, and significantly improves survival in SA-ARDS mice.
Methodological Strengths
- Mechanistic validation of BMAL1-PFKFB3 transcriptional control in AMs with functional metabolic and polarization readouts.
- Rational nanoplatform design with AM membrane hybridization, ROS-responsive release, and inhalational delivery demonstrating survival benefit in vivo.
Limitations
- Preclinical murine models; human safety, dosing, and efficacy remain to be established.
- Potential immunogenicity and scalability of membrane-hybridized DNA nanostructures require further evaluation.
Future Directions: Advance to large-animal studies and early-phase clinical trials, optimize dosing and aerosol performance, and explore combination with standard ARDS care (lung-protective ventilation, prone positioning).
Sepsis-associated acute respiratory distress syndrome (SA-ARDS) is a life-threatening complication characterized by excessive pulmonary inflammation and pulmonary edema, lacking effective treatments. This study identifies the transcription factor BMAL1 in alveolar macrophages (AMs) as a key therapeutic target. Mechanistically, BMAL1 represses the expression of the glycolytic enzyme PFKFB3 by binding to the Pfkfb3 promoter, thereby inhibiting glycolysis, M1 polarization of AMs, and the generation
3. The PPARβ/Delta-Induced Mesenchymal Stromal Cell Secretome Has Cytoprotective Effects via ANGPTL4 in a Pre-Clinical Model of Acute Lung Inflammation.
Activation of PPARβ/δ in human MSCs yields an ANGPTL4-high secretome that restores lung epithelial repair and strengthens endothelial barrier function in an ALI mouse model. Licensing MSCs with ARDS patient serum further augments therapeutic effects, and antibody blockade of ANGPTL4 abrogates protection, pinpointing ANGPTL4 as a key effector.
Impact: This work identifies a druggable, mechanistically validated mediator (ANGPTL4) to potentiate MSC-based therapies for ARDS and provides a practical licensing strategy using patient serum. It advances translational cell therapy by linking microenvironmental cues to a defined potency marker.
Clinical Implications: While preclinical, the study suggests measuring and augmenting ANGPTL4 in MSC products as a potency metric and exploring PPARβ/δ agonism or ARDS-serum licensing during manufacturing. It informs biomarker-driven release criteria and rational combination strategies for future ARDS trials.
Key Findings
- PPARβ/δ agonism increased ANGPTL4 in the hBM-MSC secretome, enhancing repair in CALU-3 epithelial assays.
- In ALI mice, the ANGPTL4-high MSC secretome improved endothelial barrier integrity and reduced clinical scores and weight loss.
- Licensing with ARDS patient serum further boosted therapeutic effects; anti-ANGPTL4 antibody abrogated protection, confirming mechanism.
Methodological Strengths
- Mechanistic validation with gain-of-function (PPARβ/δ agonism) and loss-of-function (anti-ANGPTL4 blockade).
- Translational relevance using human ARDS patient serum licensing across in vitro and in vivo models.
Limitations
- Preclinical models (LPS-induced ALI) may not capture full ARDS heterogeneity and comorbidities.
- Safety and scalability of PPARβ/δ modulation and ANGPTL4 upregulation were not assessed.
Future Directions: Evaluate ANGPTL4-guided MSC product release criteria, test PPARβ/δ licensing in large-animal lung-injury models, and assess safety/PK of ANGPTL4-centric strategies prior to early-phase ARDS trials.
Human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) are known to exert immunomodulatory and pro-reparative effects in vivo. This makes hBM-MSCs an enticing therapeutic candidate for inflammatory diseases, such as acute respiratory distress syndrome (ARDS). The ARDS microenvironment is complex and contains an abundance of free fatty acids (FFAs), which are known to differentially impact MSC functionality. PPARβ/δ is a ubiquitously expressed nuclear receptor that is activated in response to FFA-binding. PPARβ/δ has been shown to impact the therapeutic efficacy of mouse MSCs. This study sought to investigate the impact of PPARβ/δ-modulation on human MSC functionality in vitro and in vivo. hBM-MSCs were exposed to a synthetic PPARβ/δ agonist/antagonist in the presence or absence of ARDS patient serum and the immunomodulatory and pro-reparative capacity of the MSC secretome was investigated using in vitro assays and a pre-clinical model of LPS-induced acute lung inflammation (ALI). Our results highlighted enhanced pro-reparative capacity of PPARβ/δ-agonized hBM-MSCs secretome in CALU-3 lung epithelial cells, mediated by MSC derived angiopoietin-like 4 (ANGPTL4). PPARβ/δ-induced ANGPTL4-high MSC secretome facilitated enhanced endothelial barrier integrity in the lungs of ALI mice. Therapeutic effects of PPARβ/δ-agonized hBM-MSCs secretome were further enhanced by licensing MSCs with human ARDS patient serum. ARDS-licensed PPARβ/δ-induced ANGPTL4-high MSC secretome had reduced clinical score and weight loss. The role ANGPL4 in these protective effects was confirmed using an anti-ANGPTL4 antibody. These findings conclude that the MSC secretome therapeutic effects can be enhanced both in vitro and in vivo through licensing strategies that upregulate the angiogenic factor ANGPTL4.